BAD HOMBURG — At the forefront of innovation in renal care, Fresenius Medical Care (FME) has launched a cutting-edge “Augmented Reality” (AR) application aimed at revolutionizing the training process for nursing staff in Intensive Care Units (ICUs) worldwide, according to a press release published on EuropaWire.

The newly introduced AR application, designed to enhance learning efficiency, combines advanced AR glasses with digital learning modules tailored to the intricacies of Kidney Replacement Therapy. Through these AR glasses, nursing professionals gain immersive, on-site training experiences with acute dialysis machines directly within ICU settings. The glasses stream visual and acoustic instructions, providing real-time guidance as users interact with the dialysis equipment.

Dr. Katarzyna Mazur-Hofsäß, a key member of Fresenius Medical Care’s Management Board overseeing Care Enablement, expressed the company’s commitment to leveraging technology for the betterment of patient care. “Our innovative solution is designed to ensure that nursing staff, particularly those in Intensive Care Units, are equipped with the knowledge needed to provide high-quality and exceptional patient care,” Dr. Mazur-Hofsäß stated.

The AR glasses facilitate self-guided, on-demand education for critical care professionals, offering training modules covering various aspects of machine operation, including setup procedures, citrate pump activation, and component handling. Fresenius Medical Care showcased the Augmented Reality learning program, Ready4 multiFiltratePRO AR, at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels.

The Ready4 multiFiltratePRO AR training application is set to debut in select markets as early as the second quarter of 2024, with plans for subsequent expansion into additional regions, including Europe, the Middle East, Africa, and the Asia Pacific. A limited rollout in the United States is scheduled for later this year, with a full launch anticipated in 2025 following the successful completion of the Safety of Regional Citrate Anticoagulation (SARCA) trial.

Addressing the pressing issue of nursing shortages and staff turnover rates in ICUs worldwide, this innovative training approach aims to provide flexible, high-quality education to meet the evolving demands of the healthcare industry.

Ready4 multiFiltratePRO AR is specifically tailored for use with Fresenius Medical Care’s Continuous Kidney Replacement Therapy system, the multiFiltratePRO, which is currently deployed in over 40 countries globally.

For more information about Ready4 multiFiltratePRO AR, visit the dedicated page on the Fresenius Medical Care website: Ready4 multiFiltratePRO AR.